UNICEF

New York City, New York, United States
New York City, New York, United States
SEARCH FILTERS
Time filter
Source Type

Freshdesk, the leading provider of cloud-based customer engagement software, announced that Western Sussex Hospitals has implemented cloud-based IT Service Management platform Freshservice to provide support and self-service functionality to more than 6,500 users at the Trust. Post go-live with Freshservice, Western Sussex Hospitals has seen an organisation-wide improvement in productivity thanks to increased self-service use, better IT service delivery and support processes, and greater customer satisfaction. The change in tool is also predicted to result in a significant cost saving over the next five years. Given the complex IT environment of an acute hospital, the IT team faces significant pressures in being responsible for quickly resolving IT issues that directly affect patient care. Faced with organisation-wide discontent with the existing IT service desk, Grant Harris, Head of IT Operations at Western Sussex Hospitals, decided that an in-house service desk tool would help to resolve many of their issues. However, one of the toughest challenges in the project was the need to set up the new service desk within three months due to the outsourced service desk contract coming to an end. The team was thus faced with a delivery deadline that couldn’t be extended at any cost. “Western Sussex was rated as ‘Outstanding’ by the CQC (Care Quality Commission) in 2016 and the aim was to have an Outstanding IT service that matches the clinical services the Trust delivers. The team at Freshdesk was willing to go the extra mile to make sure the system met our needs,” commented Grant Harris, Head of IT Operations at Western Sussex Hospitals. “The look and feel of Freshservice is totally different from our previous tool; it works more like an email inbox than a standard list of outstanding jobs. Overall, Freshservice has been one of the best tools we have worked with – we found the configuration of Freshservice very easy to learn, and were able to automate many of the important workflows in a matter of weeks.” Freshservice’s ease of configuration and customisation, especially in getting the self-service portal to suit their end-users’ requirements, delivered Western Sussex significant improvements across the organisation, beginning with improved perception of the IT team. Automation also proved to be another big win for Western Sussex. Freshservice has notably reduced the time spent on calls, improved service level agreement (SLA) achievement by ensuring that the right IT support team member gets relevant tickets, and relieved the pressure on their busy IT team. Self-service usage has already improved from 10% to 34%, increasing productivity for both agents and users, while end-users need only wait 20 seconds for an agent to pick up their ticket, as compared to 15 minutes with the old tool. Simon Johnson, UK General Manager at Freshdesk commented, “Any time spent waiting for IT support and service in a clinical environment is time when patient care can be held up. At the same time, NHS organisations are continually tasked with finding new efficiency savings and cost reductions. Using cloud-based service management, the IT team at Western Sussex has improved service levels and reduced cost. As a side benefit, the IT team at the Trust has seen improvements in how its services are perceived in general, making it easier to collaborate around other IT projects in future.” In recognition of the success of the Freshservice implementation, the IT Solutions team at Western Sussex was awarded an international award for Best Implementation of an IT Service Management Solution by the Service Desk Institute. About Western Sussex Hospitals NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust serves a population of 450,000 people across a catchment area covering most of West Sussex. The Trust runs three hospitals: St. Richard’s Hospital in Chichester, Southlands Hospital in Shoreham-by-Sea, and Worthing Hospital in the center of Worthing. Western Sussex became an NHS Foundation Trust on 1 July 2013, just over four years after the organisation was created by a merger of the Royal West Sussex and Worthing, and Southlands Hospitals NHS trusts. http://www.westernsussexhospitals.nhs.uk About Freshservice Freshservice is a cloud-based IT service desk and IT service management (ITSM) solution that is quick to set up and easy to use and manage across the organisation. Freshservice is built on the proven Freshdesk platform, whose flagship customer service offering supports more than 80,000 customers worldwide, including Honda, 3M, Macmillan, Bridgestone, and UNICEF. https://freshservice.com/ About Freshdesk Freshdesk is a cloud-based customer support platform that was founded with the mission of enabling companies of all sizes to provide great customer service. The company’s goal is simple: make it easy for brands to talk to their customers and make it easy for users to get in touch with businesses. https://freshdesk.com


News Article | May 11, 2017
Site: www.prnewswire.co.uk

Representatives of international organizations, the scientific community as well as non-government organizations and businesses will take part in the event. In general, the business agenda of Astana EXPO 2017 is expected to be very rich. It will include the Ministerial Conference "Meeting the Challenge of Sustainable Energy", the World Conference on Tourism and Future Energy: Unlocking Low-Carbon Growth Opportunities (UNWTO). The Summit of the Shanghai Cooperation Organization in Astana chaired by the Republic of Kazakhstan will become a significant event in the lead-up to the opening ceremony of EXPO 2017. Besides, the 14th Eurasian Media Forum, the 11th KAZENERGY Eurasian forum and a lot of thematic conferences will be held during EXPO 2017 with participation of world-renowned scientists, Nobel Laureates and other energy experts. Heads of states, managers of major global and Kazakhstani companies, including Shell, Samsung, NCOC, JSC "Samruk-Energy", sponsors of the exhibition, as well as representatives of international organizations such as the UN, UNESCO, UNICEF, IRENA, World Bank, OPEC and others are expected to attend EXPO 2017. Based on the results of EXPO 2017, countries participating in it will sign the Manifesto of Values and Principles following the example of the Kyoto Protocol. The concept of this document, which will become the intellectual legacy of the exhibition, is currently being developed. Therefore, EXPO 2017 should mark a turning point in development of green energy at the world level. The Astana EXPO-2017 International Specialized Exhibition is dedicated to Future Energy. It is an educational and recreational event that will take place between 10 June and 10 September 2017 in Astana. The exhibition will last 93 days and will be one of the most spectacular cultural venues of 2017. As part of Astana EXPO 2017, global policy documents will be drafted to promote an energy-efficient lifestyle and wide use of renewable energy sources.


News Article | May 8, 2017
Site: news.yahoo.com

Nairobi (AFP) - War has now forced more than one million children to flee South Sudan and uprooted 1.4 million others within the country, the United Nations said on Monday. Children make up 62 percent of the 1.8 million people who have fled South Sudan for refugee camps in neighbouring Ethiopia, Kenya and Uganda since civil war began in 2013, the UN children's agency, UNICEF, and refugee agency, UNHCR, said in a joint press release. Another 1.4 million children are living in camps inside South Sudan. "The future of a generation is truly on the brink," said UNICEF's Leila Pakkala. "The horrifying fact that nearly one in five children in South Sudan has been forced to flee their home illustrates how devastating this conflict has been for the country's most vulnerable," she said. South Sudan won its independence in 2011 but two years later a new conflict began when President Salva Kiir accused his former deputy Riek Machar of planning a coup. The war quickly spread, splitting the country along ethnic lines and triggering famine in some areas earlier this year. "No refugee crisis today worries me more than South Sudan," said Valentin Tapsoba of the UNHCR. Tens of thousands of people have been killed in the ongoing conflict, among them more than 1,000 children, the UN added. Children have not only been victims of the violence and abuse, but perpetrators, forcibly recruited into armed groups and deployed in the fight against opposing soldiers and in the brutal attacks on civilians that have defined the conflict. UNICEF said it has raised just over half of the $181 million (164 million euros) needed to help South Sudanese refugees this year, while the UNHCR said it has only received 11 percent of the $782 million it needs. Competing conflicts and crises around the world mean that aid agencies are struggling to get the funds they need to do their work.


News Article | May 9, 2017
Site: www.accesswire.com

DUBAI, UAE / ACCESSWIRE / May 9, 2017 / A water purification system that uses nanotechnology to remove bacteria, viruses, and other contaminants may be the solution to delivering clean drinking water to rural communities. The best part - it could cost as low as $3 per family. Researchers from the Indian Institute of Technology Madras in Chennai, India developed a purification device. This device filters water through a crafted mixture of nanoparticles to remove harmful contaminants. The National Academy of Sciences published this study in their journal proceedings on May 6, 2013. Professor Thalappil Pradeep, of the Department of Chemistry at the Indian Institute of Technology Madras, says the device is currently being tested in some small communities in India. According to Pradeep, the system can offer an affordable way to provide families with at least 10 liters (2.6 gallons) of safe drinking water per day. Is It Enough For A Family? "For a family of five in a rural Indian village, you probably need some water in the morning for cooking and some water for drinking," Pradeep explained. "We figure 9 to 10 liters is good enough for those purposes. Then, you can fill it up again, and you now have 20 liters for the day." 11% of the global population, or 783 million people, do not have access to clean drinking water, according to the World Health Organization and UNICEF Joint Monitoring Programme for Water Supply and Sanitation. Pradeep thinks this new system could fulfill the need for clean affordable water in rural areas around the globe. "We're implementing this already on a community scale, looking at regional water problems," Pradeep said. "But arsenic is a big problem in Africa and other places, and we are interacting with people about it." What this Means for Yemen Currently, the water supply and sanitation in Yemen is facing many challenges. The biggest one, water, especially in the Highlands, quoting The Times of London that, "Yemen could become the first nation to run out of water." 50% of the population struggle daily to find or buy enough clean water to drink or grow food. As a result, 14.7 million Yemenis depend on humanitarian aid. Due to the country's hot climate, Yemen is prone to water shortage. The problem has worsened due to an increasing population and poor water management. Rather than collecting and storing rainwater, drilling for limited groundwater became the trend. Various estimates foresee capital Sana'a could run out of water within a decade. In Sana'a, which is an urban area, 40% of the houses are connected to pipes. However, In the rural areas, some women spend up to 5 hours of their day collecting water. This new purification system gives hope that there could soon be a solution for the current water shortage in Yemen. Haitham Alaini is a Yemeni entrepreneur and philanthropist. He received a degree in economics from George Washington University, and upon his return to Yemen, created his own construction business specializing in oil and gas infrastructure. Over the course of the last twenty years, the Yemeni patriot has gained invaluable experience, as well as attained a profound respect for the professionals of Yemen and its surrounding regions. Alaini is passionate about exploring innovative technology that will help improve Yemen, his native country. To learn more about Haitham Alaini visit:


In addition to keynote and panel presentations, the Summit will include customized content tracks for each financial segment, Leadership Skills workshops, and Introduction and Alumni master classes on Exponential Technologies. There will also be a hands-on Innovation Lab featuring the latest disruptive technologies. The Summit is designed to provide insights on how to take action, remove uncertainty and instill confidence in where to make investments to remain competitive and secure. This year's Summit will focus on: "Exponential Finance will help attendees navigate the rapid pace of change taking place in the financial sector due to exponential technologies.  We'll share tools that will help participants stay at the forefront and understand where to invest, how to protect their assets, and what it will take to remain competitive and successful in this new economy," said Will Weisman, Executive Director, Summits at SU. Among the presenters and topics this year: Exponential Finance is one of three Exponential Summits each year, the other two are  Exponential Manufacturing and Exponential Medicine. SU also hosts an annual Global Summit and a growing number of International Summits. The Summits foster technology innovation and the real-world applications that drive global good. To date, Summits have attracted attendees from 85 countries who network with each other and domain experts in exponential technologies and thinking. During these unique events, attendees gain actionable knowledge and skills along with a network of industry contacts to help them navigate how these disruptive technologies can be incorporated into and benefit their organizations. Exponential Finance is produced with generous support from Deloitte, Platinum Partner of Singularity University Summits, as well as from CNBC, the Exponential Finance Media Partner and the following Partners of Exponential Finance:  RealLeaders, b37.vc, Barron's, sifma, YPO WPO, crowdfunder, and Financial Advisor. Registration, full speaker lineup, and working agenda are available at https://su.org/summits/exponential-finance/ Press inquiries? Ask questions or register here: https://su.org/summits/exponential-finance/ ABOUT SINGULARITY UNIVERSITY (SU) Singularity University is a global learning and innovation community using exponential technologies to tackle the world's biggest challenges and build an abundant future for all. SU's collaborative platform empowers individuals and organizations across the globe to learn, connect, and innovate breakthrough solutions using accelerating technologies like artificial intelligence, robotics, and digital biology. SU was founded in 2008 by renowned innovators Ray Kurzweil and Peter H. Diamandis and is partnered with leading organizations including Google, Deloitte, Genentech, and UNICEF. To learn more, visit SU.org, join us on Facebook, follow us on Twitter @SingularityU and download our SingularityU Hub mobile app from the App Store. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/singularity-university-2017-financial-summit-will-focus-on-how-to-prepare-for-exponential-opportunities-and-disruptions-coming-to-world-economy-300456208.html


News Article | May 11, 2017
Site: www.prnewswire.com

Representatives of international organizations, the scientific community as well as non-government organizations and businesses will take part in the event. In general, the business agenda of Astana EXPO 2017 is expected to be very rich. It will include the Ministerial Conference "Meeting the Challenge of Sustainable Energy", the World Conference on Tourism and Future Energy: Unlocking Low-Carbon Growth Opportunities (UNWTO). The Summit of the Shanghai Cooperation Organization in Astana chaired by the Republic of Kazakhstan will become a significant event in the lead-up to the opening ceremony of EXPO 2017. Besides, the 14th Eurasian Media Forum, the 11th KAZENERGY Eurasian forum and a lot of thematic conferences will be held during EXPO 2017 with participation of world-renowned scientists, Nobel Laureates and other energy experts. Heads of states, managers of major global and Kazakhstani companies, including Shell, Samsung, NCOC, JSC "Samruk-Energy", sponsors of the exhibition, as well as representatives of international organizations such as the UN, UNESCO, UNICEF, IRENA, World Bank, OPEC and others are expected to attend EXPO 2017. Based on the results of EXPO 2017, countries participating in it will sign the Manifesto of Values and Principles following the example of the Kyoto Protocol. The concept of this document, which will become the intellectual legacy of the exhibition, is currently being developed. Therefore, EXPO 2017 should mark a turning point in development of green energy at the world level. The Astana EXPO-2017 International Specialized Exhibition is dedicated to Future Energy. It is an educational and recreational event that will take place between 10 June and 10 September 2017 in Astana. The exhibition will last 93 days and will be one of the most spectacular cultural venues of 2017. As part of Astana EXPO 2017, global policy documents will be drafted to promote an energy-efficient lifestyle and wide use of renewable energy sources.


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors. Dr. Leire has currently been the CEO of DanDrit Biotech (OTCQB:DDRT) which is developing a dendritic cell-based immunotherapy for the treatment of advanced colorectal cancer (Phase III clinical trials). He also serves on the Board of Novicol International Holding Inc., a Canadian company with a microbicide commercially available in China. Dr. Leire brings to Blake Insomnia Therapeutics a valued combination of medical professionalism with business acumen spanning over 30 years encompassing: - Biotech - held executive positions with Paringenix, APT Therapeutics, and Biostrategies Group; - Pharmaceutical - served in senior management at Pfizer, Boots Pharma, Schering Plough Pharmacia; - Private Equity - partner at Biofund Venture and Medwell Capital; - Non-Profit - HIV/AIDS Project Manager with Doctors of the World, establishing educational programs and coordinating with United Nations organization such as UNHCR, UNAIDS, UNICEF and UNDP; and - Academia - Research Associate at the Harvard University AIDS Institute. Dr. Eric Leire earned his MD from Grenoble University Medical School in Grenoble, France, and also holds an MBA with a Finance specialization from Institute Superieure des Affaires in Paris, France and a MBA with a Health Care Management specialization from the Kellogg Graduate School of Management, Northwestern University in Chicago, IL. “We are very happy Dr. Leire has accepted an appointment to our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Dr. Leire is a highly accomplished doctor and executive with an international mindset and a demonstrated ability to creatively produce tangible results in the pharmaceutical and biotech industries. We are fully assured he has the qualifications and range of experience to advance the company to the position of being the premier quality of life provider though sleep enhancement.” Dr. Leire’s experience in the biotech industry, brings strong merit and expertise to Blake Insomnia’s future plans to engage drug regulatory agencies and conduct clinical trials. It is important to note that the Biotech industry possess the most stringent regulatory procedures that need to be fulfilled in order to achieve market approval. Given the strategic position of ZLX-1 compound and the large unmet clinical need for insomnia sufferers, Dr. Leire welcomes the opportunity to improve patient access to much needed treatment and will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance. Blake Insomnia Therapeutics Inc. Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors. Dr. Leire has currently been the CEO of DanDrit Biotech (OTCQB:DDRT) which is developing a dendritic cell-based immunotherapy for the treatment of advanced colorectal cancer (Phase III clinical trials). He also serves on the Board of Novicol International Holding Inc., a Canadian company with a microbicide commercially available in China. Dr. Leire brings to Blake Insomnia Therapeutics a valued combination of medical professionalism with business acumen spanning over 30 years encompassing: - Biotech - held executive positions with Paringenix, APT Therapeutics, and Biostrategies Group; - Pharmaceutical - served in senior management at Pfizer, Boots Pharma, Schering Plough Pharmacia; - Private Equity - partner at Biofund Venture and Medwell Capital; - Non-Profit - HIV/AIDS Project Manager with Doctors of the World, establishing educational programs and coordinating with United Nations organization such as UNHCR, UNAIDS, UNICEF and UNDP; and - Academia - Research Associate at the Harvard University AIDS Institute. Dr. Eric Leire earned his MD from Grenoble University Medical School in Grenoble, France, and also holds an MBA with a Finance specialization from Institute Superieure des Affaires in Paris, France and a MBA with a Health Care Management specialization from the Kellogg Graduate School of Management, Northwestern University in Chicago, IL. “We are very happy Dr. Leire has accepted an appointment to our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Dr. Leire is a highly accomplished doctor and executive with an international mindset and a demonstrated ability to creatively produce tangible results in the pharmaceutical and biotech industries. We are fully assured he has the qualifications and range of experience to advance the company to the position of being the premier quality of life provider though sleep enhancement.” Dr. Leire’s experience in the biotech industry, brings strong merit and expertise to Blake Insomnia’s future plans to engage drug regulatory agencies and conduct clinical trials. It is important to note that the Biotech industry possess the most stringent regulatory procedures that need to be fulfilled in order to achieve market approval. Given the strategic position of ZLX-1 compound and the large unmet clinical need for insomnia sufferers, Dr. Leire welcomes the opportunity to improve patient access to much needed treatment and will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance. Blake Insomnia Therapeutics Inc. Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors. Dr. Leire has currently been the CEO of DanDrit Biotech (OTCQB:DDRT) which is developing a dendritic cell-based immunotherapy for the treatment of advanced colorectal cancer (Phase III clinical trials). He also serves on the Board of Novicol International Holding Inc., a Canadian company with a microbicide commercially available in China. Dr. Leire brings to Blake Insomnia Therapeutics a valued combination of medical professionalism with business acumen spanning over 30 years encompassing: - Biotech - held executive positions with Paringenix, APT Therapeutics, and Biostrategies Group; - Pharmaceutical - served in senior management at Pfizer, Boots Pharma, Schering Plough Pharmacia; - Private Equity - partner at Biofund Venture and Medwell Capital; - Non-Profit - HIV/AIDS Project Manager with Doctors of the World, establishing educational programs and coordinating with United Nations organization such as UNHCR, UNAIDS, UNICEF and UNDP; and - Academia - Research Associate at the Harvard University AIDS Institute. Dr. Eric Leire earned his MD from Grenoble University Medical School in Grenoble, France, and also holds an MBA with a Finance specialization from Institute Superieure des Affaires in Paris, France and a MBA with a Health Care Management specialization from the Kellogg Graduate School of Management, Northwestern University in Chicago, IL. “We are very happy Dr. Leire has accepted an appointment to our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Dr. Leire is a highly accomplished doctor and executive with an international mindset and a demonstrated ability to creatively produce tangible results in the pharmaceutical and biotech industries. We are fully assured he has the qualifications and range of experience to advance the company to the position of being the premier quality of life provider though sleep enhancement.” Dr. Leire’s experience in the biotech industry, brings strong merit and expertise to Blake Insomnia’s future plans to engage drug regulatory agencies and conduct clinical trials. It is important to note that the Biotech industry possess the most stringent regulatory procedures that need to be fulfilled in order to achieve market approval. Given the strategic position of ZLX-1 compound and the large unmet clinical need for insomnia sufferers, Dr. Leire welcomes the opportunity to improve patient access to much needed treatment and will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance. Blake Insomnia Therapeutics Inc. Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors. Dr. Leire has currently been the CEO of DanDrit Biotech (OTCQB:DDRT) which is developing a dendritic cell-based immunotherapy for the treatment of advanced colorectal cancer (Phase III clinical trials). He also serves on the Board of Novicol International Holding Inc., a Canadian company with a microbicide commercially available in China. Dr. Leire brings to Blake Insomnia Therapeutics a valued combination of medical professionalism with business acumen spanning over 30 years encompassing: - Biotech - held executive positions with Paringenix, APT Therapeutics, and Biostrategies Group; - Pharmaceutical - served in senior management at Pfizer, Boots Pharma, Schering Plough Pharmacia; - Private Equity - partner at Biofund Venture and Medwell Capital; - Non-Profit - HIV/AIDS Project Manager with Doctors of the World, establishing educational programs and coordinating with United Nations organization such as UNHCR, UNAIDS, UNICEF and UNDP; and - Academia - Research Associate at the Harvard University AIDS Institute. Dr. Eric Leire earned his MD from Grenoble University Medical School in Grenoble, France, and also holds an MBA with a Finance specialization from Institute Superieure des Affaires in Paris, France and a MBA with a Health Care Management specialization from the Kellogg Graduate School of Management, Northwestern University in Chicago, IL. “We are very happy Dr. Leire has accepted an appointment to our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Dr. Leire is a highly accomplished doctor and executive with an international mindset and a demonstrated ability to creatively produce tangible results in the pharmaceutical and biotech industries. We are fully assured he has the qualifications and range of experience to advance the company to the position of being the premier quality of life provider though sleep enhancement.” Dr. Leire’s experience in the biotech industry, brings strong merit and expertise to Blake Insomnia’s future plans to engage drug regulatory agencies and conduct clinical trials. It is important to note that the Biotech industry possess the most stringent regulatory procedures that need to be fulfilled in order to achieve market approval. Given the strategic position of ZLX-1 compound and the large unmet clinical need for insomnia sufferers, Dr. Leire welcomes the opportunity to improve patient access to much needed treatment and will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance. Blake Insomnia Therapeutics Inc. Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.

Loading UNICEF collaborators
Loading UNICEF collaborators